Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 27, 2007

CytoGenix and USAMRIID Forge Biodefense Vaccines Partnership

  • CytoGenix entered into a CRADA with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to develop and test synDNA™ vaccines for the prevention of disease caused by the Ebola virus and several strains of equine encephalitis viruses.

    “These disease targets are listed as Category A & B bioterrorism agents/diseases by the Centers for Disease Control,” points out Malcolm Skolnick, CEO.

    “Data collected under this CRADA will help to demonstrate the validity of use of synDNA™ vaccines in rapid response platforms, including the protection of our nation’s military personnel, health providers and other first responders, as well as the general population against a spectrum of existing and emerging terroristic and other infectious diseases.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »